Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating Associations Between Cumulative Use of Chronic Liver Injury-Inducing Antiretroviral Therapy and Hepatocellular Carcinoma, By Chronic Liver Disease Status.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Saliva as a noninvasive diagnostic for ocular sarcoidosis.

Journal of leukocyte biology·2026
Same author

Oral cyclophosphamide as part of the treatment regimen in patients with nonparaneoplastic autoimmune retinopathy secondary to birdshot chorioretinopathy.

Oman journal of ophthalmology·2026
Same author

How to interpret low-dose valacyclovir for postherpetic neuralgia in the Zoster Eye Disease Study-a randomized clinical trial.

Annals of translational medicine·2026
Same author

Association Between Congenital Heart Disease Complexity, Mental Health Conditions and Opioid Use Disorder.

JACC. Advances·2025
Same author

High-Throughput Screening Using the Self-Controlled Tree-Based Scan Statistic to Identify Medications Associated With Hospitalization for Severe Acute Liver Injury.

Pharmacoepidemiology and drug safety·2025
Same journal

Reply to Comment on Visual Field Progression in Glaucoma Patients with Delayed Follow-Up.

American journal of ophthalmology·2026
Same journal

Comment on: "Safety and efficiency reducing retinopathy of prematurity guideline sensitivity: an external validation using a large US-based dataset".

American journal of ophthalmology·2026
Same journal

Reply to Comment on "Clinicopathological and Imaging Distinction Between Ocular Adnexal MALT Lymphoma and IgG4-Related Ophthalmic Disease".

American journal of ophthalmology·2026
Same journal

Comment on: Visual Field Progression in Glaucoma Patients With Delayed Follow-Up.

American journal of ophthalmology·2026
Same journal

Corneal sensitivity changes and nerve plexus abnormalities in noninfectious anterior uveitis.

American journal of ophthalmology·2026
Same journal

Role of Menopausal Hormone Therapy on Strabismus, Strabismus Surgery, and Reoperation Rates.

American journal of ophthalmology·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

Mycophenolate mofetil for ocular inflammation.

Ebenezer Daniel1, Jennifer E Thorne, Craig W Newcomb

  • 1The Fundus Photograph Reading Center, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.

American Journal of Ophthalmology
|January 1, 2010
PubMed
Summary
This summary is machine-generated.

Mycophenolate mofetil effectively managed noninfectious ocular inflammation in about half of patients. While 12% discontinued due to side effects, these were typically reversible, suggesting its utility in treating eye inflammation.

Related Experiment Videos

Last Updated: Jun 17, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

Area of Science:

  • Ophthalmology
  • Immunology

Background:

  • Noninfectious ocular inflammatory diseases require effective immunosuppressive therapy.
  • Corticosteroids are a common treatment but have significant side effects.
  • Alternative noncorticosteroid agents are needed for long-term management.

Purpose of the Study:

  • To evaluate mycophenolate mofetil as a single, noncorticosteroid immunosuppressive treatment for various noninfectious ocular inflammatory diseases.

Main Methods:

  • Retrospective cohort study of 236 patients with noninfectious ocular inflammation treated with mycophenolate mofetil monotherapy.
  • Data abstracted from medical records, focusing on inflammation control, corticosteroid-sparing effects, and drug discontinuation.
  • Kaplan-Meier survival analysis used to assess outcomes and identify risk factors.

Main Results:

  • Complete inflammation control was achieved in 53% by 6 months and 73% by 1 year.
  • Systemic corticosteroid dosage was reduced to ≤10 mg prednisone in 41% by 6 months and 55% by 1 year.
  • Twelve percent of patients discontinued mycophenolate mofetil within the first year due to reversible side effects.

Conclusions:

  • Mycophenolate mofetil monotherapy demonstrates efficacy in managing a significant proportion of patients with noninfectious ocular inflammation over time.
  • The drug offers a corticosteroid-sparing effect, aiding in reducing long-term steroid-related complications.
  • Treatment-limiting side effects occurred in 12% of patients but were generally reversible, supporting its role as a therapeutic option.